



**PHARMAGEST GROUP MAKES ANOTHER INVESTMENT
IN THE INNOVATIVE HOME-BASED HEALTHCARE SYSTEMS SECTOR
WITH A MAJORITY STAKE IN NOVIATEK**

- The PHARMAGEST Group, acting alongside its subsidiary KAPELSE acquires an 80% stake in the company NOVIATEK (www.noviatek.com), which becomes a subsidiary of the PHARMAGEST Group.
- NOVIATEK is a start-up specialising in the design of innovative systems for assisting people with specific needs (Alzheimer's, older people living alone, dependent people, people living with disabilities, etc.).
- In particular, it develops projects oriented towards Smart Homes.
- NOVIATEK is **preparing to launch a new product, Noviacare™**: a router supporting home care for people with specific needs, which works autonomously and is equipped with wireless sensors able to measure user activity.

New investment in the innovative healthcare systems sector for the PHARMAGEST Group

The PHARMAGEST Group continues to develop its technological infrastructure and services for patients, particularly in the field of home care with the acquisition of NOVIATEK, a start-up specialising in the design of innovative technological systems for assisting people with specific needs (Alzheimer's, older dependent people, people living with disabilities, etc.).

Noviacare™: a technological breakthrough on the home care market

Working closely with partners from the medical-social field, NOVIATEK has developed Noviacare™, an assistance system designed for people with Alzheimer's and older people living alone.

This system aims to assist the person and inform friends and relatives in the event of anomalies (meals not eaten, falls, hygiene issues, etc.). The system, using a few carefully placed sensors and a central router, measures the person's life at home, analyses behaviour and works preventively to reassure the person themselves, as well as their family and carers, with a report sent on a daily basis. Also equipped with a speech synthesis system, Noviacare™ can provide the person with advice on taking medication, meal frequency, hydration levels and space-time guidance.

The device is not intrusive, does not require an internet connection and is easy to install in the home (wireless, Plug&Play).

Noviacare™: the first Plug&Play system in telemedicine

The Noviacare™ assistance system required over 4 years of R&D, in partnership with laboratories, universities and associations.

The innovative aspect of the technology comes from the way it handles data, creating the lifestyle, the vocal assistance, and the system's capacity to interact with other devices (blood pressure monitor, etc.), with the objective of being the first Plug&Play system in telemedicine.

Another innovative aspect of the Noviacare™ system is its ability to learn a person's habits autonomously, allowing warnings to be managed more effectively. This learning phase, in combination with the coherent lifestyle algorithm, allows the generation of reliable warnings, and means that the user's carers and family are alerted effectively.

NOVIATEK: a start-up in a booming market

- **24 billion** euros of public spending associated with dependency, 35 billion euros by 2060.
- **1/3** of the French population aged over 50 in 2016.
- Over 80 years: **6.1 million in 2035** (+104%) and **8.4 million in 2060** (+179% on 2007).
- 95% of those aged over 75 are at home.
- **3 million** people aged over 65 live alone.
- 500,000 subscribe to simple remote assistance.
- **1,000,000 people affected by Alzheimer's disease** in France in 2012.
- **1.3 million** French people, corresponding to 1 in 4 people aged over 65, could be affected in 2020.
- **75% of people with Alzheimer's are at home.**
- Average cost of a retirement home: €2,200 per month.
- Average pension: €1,100 per month.
- Personal care allowance €600.
- Total for day and night presence at home €7,000.

The PHARMAGEST Group and NOVIATEK expect to record a level of activity of over €6 M within 5 years.

The production and marketing of Noviacare™ is scheduled for late 2017, mainly via physical points of sale in town centres. A system installation service and after-sales service will be included at these points.

PHARMAGEST INTERACTIVE financial calendar reminder:

Publication of half-year results on 12 September 2016.

About the PHARMAGEST Group:

The PHARMAGEST Group is the French leader in pharmacy information technology, with a 43.5% share of the market and over 800 employees. The strategy of the PHARMAGEST Group is based on a core business – innovating in information technology to improve healthcare – and on the development of two priority focuses: services and technologies for healthcare professionals, notably support for pharmacists in monitoring patient compliance; and technology for improving the efficacy of healthcare systems.

To roll out that strategy, the PHARMAGEST Group has developed specialised businesses, including pharmacy IT, e-Health solutions, solutions for healthcare professionals, solutions for laboratories, connected health devices and apps, and a sales financing marketplace. These businesses are divided into 4 Divisions: the Solutions for Pharmacy Division – Europe, the Solutions for Sanitary and Medico-Social Establishments Division, the Solutions for e-Health Division, and the FinTech Division.

Listed on Euronext Paris™ - Compartment B
 Indices: ENTERNEXT TECH 40, CAC @ SMALL and CAC @ All-Tradable by inclusion
 Eligible for the Long-Only Deferred Settlement Service (SRD)
 ISIN: FR0012882389 – Reuters: PHA.PA – Bloomberg: PMGI FP
PHARMAGEST shares are eligible for France's Equity Savings Plan intended to finance SMEs (PEA-PME)



For all the latest news, go to www.pharmagest.com



CONTACTS

Analyst and Investor Relations:

Chief Financial Officer: Jean-Yves SAMSON

Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@pharmagest.com

Press Relations:

FIN'EXTENSO – Isabelle APRILE

Tel. +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr